Belinostat (TCI B5888) is a potent hydroxamate-based histone deacetylase (HDAC) inhibitor supplied as a high-purity pharmaceutical research reagent for experimental use. It is primarily employed in preclinical oncology studies to investigate epigenetic mechanisms, gene expression modulation, and apoptosis induction in various cancer cell lines. This product serves as a valuable tool in HDAC inhibitor screening, drug resistance research, and combination therapy development.
TCI brochures (PDF)
- Epigenetics Research Reagents 2024-11-22 · p. 1
- Cancer Research Reagents 2025-04-01 · p. 8
- Antimicrobials and Antitumor Agents for Research and Experimental Use 2025-04-24 · p. 18
- Pharmaceutical Ingredients for Research and Experimental Use 2026-03-09 · p. 19
- Reagents for Biological Research 2025-03-11 · p. 34
—
| Brand | — |
|---|---|
| CAS number | — |
| Molecular formula | — |
| Purity | — |
| Category | — |
| Pack sizes | — |
| Physical form | — |
| Storage | — |
—
—
Product Categories
- Biochemicals and ReagentsPharmaceutical Research Reagents (for Experimental Use)Antitumor Research Reagents (for Experimental Use)
- Cell BiologyApoptosisApoptosis Inducers
- Molecular BiologyEpigeneticsBioactive Small Molecules for Epigenetic Research
- Pharmaceutical Development and Drug Discovery ResearchPharmaceutical Research Reagents (for Experimental Use)Antitumor Research Reagents (for Experimental Use)

![4-(Dimethylamino)-N-[7-(hydroxyamino)-7-oxoheptyl]benzamide (CAS 251456-60-7) - TCI D4188 - AMI Scientific](http://amiscientific.com/cdn/shop/files/TCI2510D4188.jpg?v=1767107192&width=533)






